Supernus Pharmaceuticals, Inc. (SUPN)
| Market Cap | 2.88B +61.6% |
| Revenue (ttm) | 718.95M +8.6% |
| Net Income | -38.55M |
| EPS | -0.68 |
| Shares Out | 57.58M |
| PE Ratio | n/a |
| Forward PE | 21.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 467,809 |
| Open | 50.76 |
| Previous Close | 50.46 |
| Day's Range | 49.72 - 51.81 |
| 52-Week Range | 29.16 - 59.68 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 61.60 (+23.23%) |
| Earnings Date | Feb 24, 2026 |
About SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for SUPN stock is "Strong Buy." The 12-month stock price target is $61.6, which is an increase of 23.23% from the latest price.
News
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript
Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results
Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four g...
Supernus Pharmaceuticals to Participate in March Investor Conferences
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026
ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Lunai Bioworks, Inc. Issues Letter to Shareholders
SACRAMENTO, Calif. , Feb. 9, 2026 /PRNewswire/ -- Dear Shareholders, We have completed our AI platform in the last 12 months and now it is commercial.
Supernus: Outlook For 2026 Positive, Upholding Buy Rating
Supernus remains a Buy, with shares up >50% since mid-2025 and ~25% upside projected for 2026. Qelbree drives growth, with 2026 net sales expected to exceed $450m; patent expirations are being offset ...
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
ROCKVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. ( SUPN) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Jack Khattar - Founder, President, CEO, Secretary & Director Timothy Dec - Senior VP & C...
Supernus Announces Third Quarter 2025 Financial Results
ROCKVILLE, Md., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
ROCKVILLE, Md., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals: Heading In The Right Direction
Supernus Pharmaceuticals shares have rallied nicely after strong 2Q25 results, driven by robust Qelbree and Gocovri sales and a surge in Zurzuvae revenue. Supernus' recent acquisition of Sage Therapeu...
Supernus Pharmaceuticals to Participate in September Investor Conferences
ROCKVILLE, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals, Inc. (SUPN) Q2 2025 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Jack A. Khattar - Founder, President, CEO, Secretary & Director Timothy C.
Supernus Announces Second Quarter 2025 Financial Results
ROCKVILLE, Md., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform, accelerating mid- t...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc., a Delaware corporation (NASDAQ: SUPN) ("Supernus", and the "Company"), today announced that the required waiting perio...
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
ROCKVILLE, Md., July 22, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen...
SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Sage ...
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc.
NEW YORK , June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. (NASDAQ: SAGE) and its board of directors concerning the propos...
Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal
Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.